EORTC QoL FinTox

The financial impact of cancer on the individual patient is often characterised as an objective and a subjective financial burden. The objective financial burden gives no information on how the patient himself perceives the financial impact and the consequences on his life; this view is provided by the subjective financial burden, which describes the impact and consequences of the objective costs on the patient. This often results in material consequences, psychological effects, or behavioural changes, which then are expressed as a “financial toxicity”. The currently existing tools are either only narrowly validated, are generic economic tools, are restricted to a certain health care system, are restricted to a specific cancer site, or do not cover all relevant domains of financial toxicity. The aim of this Phase I study is to develop a list of issues related to financial toxicity in cancer patients.

{ "short_title": "EORTC QoL FinTox", "data_mode": "900", "data_mode_number": "000002270", "official_title": "Development of a Module to Assess the Patients' Financial Burden Related to Cancer Treatment - Phase I", "accrual_state": "stoppedTemporarily", "therapeutic_value": "nonTherapeutic", "therapieansatz_value": "not_applicable", "therapieintervention_value": "not_applicable", "therapielinie_value": "not_applicable", "ctgov_number": null, "eudract_number": null, "general_contact_email": "martin.eichler@ukdd.de", "general_contact_phone": "+49 351-45819057", "hauptpruefer_dd_name": "Dr. Martin Eichler", "description_laie_de": "Diese Studie hat zum Ziel, einen Lebensqualit\u00e4tsfragebogen f\u00fcr Patientinnen und Patienten zu entwickeln, der die finanziellen Folgen einer Krebserkrankung und deren Auswirkungen auf den Patienten erhebt.", "description_laie_en": "The aim of this study is to develop a quality of life questionnaire for patients that assesses the financial consequences of cancer and its impact on the patient.", "description_expert_de": "Siehe den englischen Text.", "description_expert_en": "The financial impact of cancer on the individual patient is often characterised as an objective \r\nand a subjective financial burden. The objective financial burden gives no information on how \r\nthe patient himself perceives the financial impact and the consequences on his life; this view \r\nis provided by the subjective financial burden, which describes the impact and consequences \r\nof the objective costs on the patient. This often results in material consequences, \r\npsychological effects, or behavioural changes, which then are expressed as a \u201cfinancial \r\ntoxicity\u201d. The currently existing tools are either only narrowly validated, are generic \r\neconomic tools, are restricted to a certain health care system, are restricted to a specific cancer \r\nsite, or do not cover all relevant domains of financial toxicity. \r\n \r\nThe aim of this Phase I study is to develop a list of issues related to financial toxicity in \r\ncancer patients.", "rechtsgrundlage_value": "BO", "phase_amg_value": null, "main_cat_id": 1, "sub_cat_id": 2 }